Sort
82,697 grants matching “vaccine development”
Task 12: Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae
$1,046,990Edward Hook · University Of Alabama At Birmingham · N01 · FY2025 · AI
Conducting Public Health Research in China
$1,046,976Feng Zijian · Chinese Ctr-Disease Control/Prevention · U01 · FY2017 · GH
A multi-tiered approach to develop validated assays to predict efficacy of a tetravalent live attenuated Dengue Virus vaccine in Phase II and Phase III clinical trials
$1,046,952Rafick-Pierre Sekaly · Emory University · R01 · FY2020 · AI
Vanderbilt Vaccine and Treatment Evaluation Unit - DMID 21-0012
$1,046,814Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2021 · AI
NON-HUMAN PRIMATE MODELS FOR EVALUATION OF AIDS THERAPIE
$1,046,786Henry M. Jackson Fdn For The Adv Mil/Med · N01 · FY2000 · AI
Cytokines in AIDS and Cancer
$1,046,735George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine
$1,046,474Amit Praful Khandhar · Hdt Bio Corporation · R61 · FY2022 · AI
HIV-1 Reverse Transcriptase
$1,046,102Stephen H Hughes · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Developing Immune Based Therapies
$1,045,977Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Clinical Program in Pediatric Sarcomas
$1,045,977Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
US-Nigerian Cancer Control Center for Research on Implementation Science and Equity (C3-RISE)
$1,045,863Juliet Iwelunmor · Washington University · U54 · FY2023 · CA
SBIR Phase II: Molecular Diagnostics and Biological Control of Disease in Farmed Channel Catfish
$1,045,760Thomas W Schoenfeld · Lucigen Corporation · · FY2011 · TIP
UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)
$1,045,660Elizabeth L Travis · University Of Tx Md Anderson Can Ctr · U54 · FY2020 · CA
THE DEVELOPMENT OF AN EFFICACIOUS VACCINE TO REDUCE CAMPYLOBACTER IN CHICKENS
$1,045,604University Of Arizona · · FY2015 · National Institute of Food and Agriculture
Protective and pathogenic B cell epitopes in Francisella tularensis
$1,045,521Jacqueline Sharon · Boston University (Charles River Campus) · N01 · FY2011 · AI
Integrated Continuous Processing Facility for Small Molecule and Biologic Lyophilized Final Dosage Forms
$1,045,447Bernhardt L Trout · Massachusetts Institute Of Technology · U01 · FY2019 · FD
SUPPORT FOR NATIONAL PRIMATE RESEARCH CENTER
$1,045,420Joseph E Robertson · Oregon Health & Science University · P51 · FY2010 · RR
Vaccines for Extensively Drug Resistant Tuberculosis
$1,045,159William Robert Jacobs · Albert Einstein College Of Medicine · R01 · FY2013 · AI
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
$1,045,138Karen L. Kotloff · University Of Maryland Baltimore · UM1 · FY2025 · AI
TASK V17: DEVELOPMENT OF ASSAYS AND REAGENTS FOR MONKEYPOX VACCINES
$1,045,131Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2022 · AI
Developmental Core
$1,045,062Elizabeth A Klonoff · San Diego State University · U54 · FY2009 · CA
IMMUNITY TO STDS IN THE HUMAN MALE GENITAL TRACT
$1,044,965Brigham And Women'S Hospital · P01 · FY2003 · AI
Gene Therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector
$1,044,958David A Williams · Boston Children'S Hospital · U01 · FY2011 · AI
Bunyavirus biology, immunity, and countermeasure development
$1,044,844Theodore Pierson · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
CYTOKINE GENE THERAPY OF CANCER
$1,044,326University Of Pittsburgh At Pittsburgh · P01 · FY2000 · CA